An Estimate of the Cost of Hepatitis C Treatment for the Brazilian Health System

Value in Health Regional Issues

Volumn 1, Issue 2, 2012, Pages 129-135

  Blatt, Carine Raquel ^a,b,c   Bernardo, Noemia Liege Maria da Cunha ^a   Rosa, Junior Andre ^a   Bagatini, Fabiola ^a   Alexandre, Rodrigo Fernandes ^d   Balbinotto Neto, Giacomo ^e   Siebert, Uwe ^b,f,g,h   Rocha Farias, Mareni ^a,b  

^a SANTA CATARINA STATE UNIVERSITY   (Brazil)

^b UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^c UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^d MINISTÉRIO DA SAÚDE   (Brazil)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f Oncotyrol Center for Personalized Cancer Medicine   (Austria)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Direct cost; Hepatitis C; Hepatitis C treatment; Interferon

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; COLONY STIMULATING FACTOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

ANEMIA; ARTICLE; BRAZIL; CONSULTATION; DIAGNOSTIC TEST; DRUG COST; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HEPATITIS C; HOSPITALIZATION; HUMAN; NEUTROPENIA; NURSING CARE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; UNSPECIFIED SIDE EFFECT;

EID: 84870916234     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2012.10.001     Document Type: Article

References (29)

1. Wogart J.P., Calcagnotto G. Brazil's fight against AIDS and its implications for global health governance. World Health Popul 2006, 8:4-19.
2. Castelo A., Pessoa M.G., Barreto T.C., et al. Cost estimates of chronic hepatitis B virus for the Brazilian unified health system in 2005. Rev Assoc Med Bras 2007, 53:486-491.
3. Diament D. Epidemiological aspects of hepatitis C in Brazil. Brazilian J Infect Dis 2007, 11(Suppl. 1):6-7.
4. Poynard T., McHutchison J., Davis G.L., et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000, 32:1131-1137.
5. Grant W.C., Jhaveri R.R., McHutchison J.G., et al. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 2005, 42:1406-1413.
6. Shepherd J., Jones J., Hartwell D., et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007, 11:1-205. iii.
7. Vieira F.S. Ministry of Health's spending on drugs: program trends from 2002 to 2007. Rev Saude Publica 2009, 43:674-681.
8. Carias C.M., Vieira F.S., Giordano C.V., Zucchi P. Exceptional circumstance drug dispensing: history and expenditures of the Brazilian Ministry of Health. Rev Saude Publica 2011, 45:233-240.
9. Strader D.B., Wright T., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
10. Bacon B.R., McHutchison J.G. Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care 2005, 11(10, Suppl.):S296-306. quiz S7-11.
11. McHutchison J.G., Manns M., Patel K., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069.
12. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64, quiz 14-7.
13. Blatt CR. Um olhar sobre a efetividade e custos do tratamento da hepatite C sob a perspectiva do Sistema Único de Saúde [Tese]. Florianópolis: Universidade Federal de Santa Catarina, 2011.
14. o 34, de 28 de setembro de 2007. Aprova o Protocolo Clínico e Diretrizes Terapĉuticas - hepatite viral C. Brasília, DF: 28 de setembro de 2007, 2007.
15. Bernardo NLMdC. Oportunidade de intervenção farmacĉutica no tratamento de pacientes com hepatite viral C crÔnica: estudo de caso no município de Itajaí/SC. [Dissertação]. Florianópolis: Programa de Pos-Graduação em Farmácia, 2010.
16. Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do SUS - Sigtap [database on the Internet]. 2010. Available from: [Accessed June 9, 2010]. http://sigtap.datasus.gov.br/tabela-unificada/app/sec/inicio.jsp.
17. Brasil. Protocolo Clínico e Diretrizes Terapĉuticas para Hepatite Viral C e coinfecções. In: Saúde Md, ed. Séria A ed. Brasília: Secretária de Vigilância em Saúde, 2011.
18. Rosa J.A.D. Tratamento de pacientes com hepatite crÔnica pelo vírus C: A experiĉncia do Pólo de Aplicação e Monitoramento de Medicamentos Injetáveis do Hospital Nereu Ramos de 2005 a 2008. [Dissertação]. Florianópolis: Universidade Federal de Santa Catarina, 2009.
19. Conversão de moedas do Banco do Brasil [database on the Internet]. 2010. Available from: [Accessed June 9, 2010]. http://www4.bcb.gov.br/pec/conversao/Resultado.asp?idpai=convmoeda.
20. Brasil. Boletim Epidemiológico - Hepatites Virais. 2010;Ano I - n° 1.
21. Sroczynski G., Esteban E., Conrads-Frank A., et al. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat 2010, 17:34-50.
22. Bacon B.R. Managing hepatitis C. Am J Manag Care 2004, 10(2, Suppl.):S30-40.
23. Patel K., Muir A.J., McHutchison J.G. Diagnosis and treatment of chronic hepatitis C infection. BMJ 2006, 332:1013-1017.
24. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36(5, Suppl. 1):S237-244.
25. McHutchison J.G., Manns M.P., Brown R.S., et al. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007, 102:880-889.
26. National Institutes of Health. Consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
27. Amaral K.M., Reis J.G.D., Picon P.D. Atenção Farmacĉutica no Sistema Único de Saúde: um exemplo de experiĉncia bem sucedida com pacientes portadores de hepatite C. Rev Bras Farm 2006, 87:3.
28. Siebert U., Wasem J., Rossol S., et al. Antiviral treatment initiation costs in chronic hepatitis C. Gut 2005, 54:172-173.
29. McHutchison J.G., Bacon B.R. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 2005, 11(10, Suppl.):S286-295. quiz S307-11.